A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD
This study compared the efficacy and safety of once-daily umeclidinium 62.5 µg with once-daily glycopyrronium 50 µg in patients with moderate-to-severe chronic obstructive pulmonary disease. This was a 12-week, multicentre, randomised, open-label, parallel-group study (Clinicaltrials.gov: NCT0223661...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2016-04-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/2/2/00101-2015.full |